News Releases

$

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Hero Chart

- CANbridge to lead development and commercialization in China ; expands rare disease pipeline - Mirum is entitled to receive up to an aggregate of $120.0 million in upfront and milestone payments, and significant double-digit tiered royalties FOSTER CITY, Calif. & BEIJING --(BUSINESS WIRE)--Apr.
... Read More
Additional Formats
- Methods of use patent expected to provide patent protection through 2040. FOSTER CITY, Calif. --(BUSINESS WIRE)--Apr. 26, 2021-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a
... Read More
Additional Formats
FOSTER CITY, Calif. --(BUSINESS WIRE)--Apr. 12, 2021-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on April 12, 2021 , the Compensation Committee of Mirum’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 118,800 shares of common stock to
... Read More
Additional Formats
- Mirum expands potential opportunities across rare disease pipeline - Vivet to lead pre-clinical development of its two gene therapy programs for PFIC3 and PFIC2 - Mirum gains option to license VTX-803 and VTX-802 FOSTER CITY, Calif. & PARIS--(BUSINESS WIRE)--Apr.
... Read More
Additional Formats
- PDUFA action date is September 29, 2021 . - Priority review and Rare Pediatric Disease Designation granted. - FDA has indicated that advisory committee is not currently planned. FOSTER CITY, Calif. --(BUSINESS WIRE)--Mar. 29, 2021-- Mirum Pharmaceuticals, Inc.
... Read More
Additional Formats
FOSTER CITY, Calif. --(BUSINESS WIRE)--Mar. 10, 2021-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on March 10, 2021 , the Compensation Committee of Mirum’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 114,800 shares of common stock to
... Read More
Additional Formats
- U.S. launch of maralixibat for Alagille syndrome (ALGS) planned for second half of 2021, if approved by FDA - Phase 2b programs initiated in Primary Sclerosing Cholangitis, Intrahepatic Cholestasis of Pregnancy and Biliary Atresia - Financial runway expected to support maralixibat launch in U.S.
... Read More
Additional Formats
FOSTER CITY, Calif. --(BUSINESS WIRE)--Feb. 22, 2021-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that the company will participate in the following upcoming virtual investor conferences: SVB Leerink 10 th Annual Global Healthcare Conference Friday, February 26, 2021 at 3:40 p.m.
... Read More
Additional Formats
FOSTER CITY, Calif. --(BUSINESS WIRE)--Feb. 10, 2021-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on February 10, 2021 , the Compensation Committee of Mirum’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 21,500 shares of common stock
... Read More
Additional Formats
- Maralixibat U.S. launch expected in second half of 2021, if approved FOSTER CITY, Calif. --(BUSINESS WIRE)--Feb. 1, 2021-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced it has completed submission of its rolling New Drug Application (NDA) to the U.S.
... Read More
Additional Formats